Towards a simple
journey in UC

JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

A simple choice. JYSELECA 200 mg is a convenient, efficacious and rapid treatment that is generally well tolerated1,2

Rapid symptomatic improvement (nominal p<0.05 vs. placebo, post hoc analysis):

  • Stool frequency subscore of ≤1 from as early as Day 3 in Biologic-Naïve patients
  • Rectal bleeding subscore of 0 from as early as Day 5 in Biologic-Experienced patients

Achieved Week 58 clinical remission (p<0.0001, primary endpoint), histologic remission and ≥6-month corticosteroid-free clinical remission (p<0.0001 and p<0.01, respectively, secondary endpoints)2


Long-term reductions in partial Mayo Clinic Score maintained up to 3.9 years3


JAK1-preferential inhibitor that has been generally well tolerated, with a consistent safety profile across clinical trials2


Convenient oral formulation, once-daily tablet2


JYSELECA 200 mg may help improve quality of life for your patients with UC (nominal p<0.05 vs. placebo, post hoc analysis)4

References: 1. Danese S, Ferrante M, Feagan BG, et al. Am J Gastroentrol 2022;118:138–147. 2. Feagan BG, Danese S, Loftus EV Jr, et al. Lancet 2021;397:2372–2384. 3. Feagan BG, Matsuoka K, Rogler G, et al. ECCO 2023. OP35. 4. Schreiber S, Feagan BG, Peyrin-Biroulet L, et al. J Crohn's Colitis 2023;jjad018.


INDICATIONS: JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

GB-UC-JY-202303-00003  | Date of preparation: April 2023